Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 10/20 | 0.51 |
| ▸ | CLK2 | P49760 | 3/20 | 0.51 |
| ▸ | CLK3 | P49761 | 3/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.51 |
| ▸ | WNT1 | P04628 | 6/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998342 | 0.85 | MAP3K8 (0.69) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15868962 | 0.73 | WNT1 (0.69) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL15868937 | 0.73 | DYRK1A (0.73) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL15868972 | 0.72 | DYRK1A (0.66) | MAP3K8CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL15868984 | 0.72 | DYRK1A (0.68) | MAP3K8CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL15862526 | 0.72 | CLK2 (0.68) | MAP3K8CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL15869000 | 0.71 | WNT1 (0.84) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL5512304 | 0.71 | MAP3K8 (0.69) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15869102 | 0.71 | WNT1 (0.82) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL5525177 | 0.70 | MAP3K8 (0.57) | MAP3K8CLK2CLK3DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |